Yes. UnitedHealthcare covers Spravato (esketamine) for treatment-resistant depression in Maryland when prior authorization criteria are met (per UHC PA/Medical Necessity Policy 2025 P 2168-10, effective May 1, 2025). UHC's commercial Spravato PA, when approved, runs for 12 months on first issuance — among the longer initial authorizations of major Maryland commercial payers (CareFirst issues a 1-month initial / 3-month continuation; Aetna runs a 6-month reauthorization).
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
UnitedHealthcare's commercial Spravato coverage is governed by UHC PA/Medical Necessity Policy 2025 P 2168-10 (effective May 1, 2025; last P&T review 3/2025):
This summary applies to UnitedHealthcare commercial medical plans. UnitedHealthcare Community Plan of Maryland (UHC's HealthChoice managed-care product) operates under separate Medicaid criteria, not commercial PA. Lumin Health verifies your specific plan during your consultation.
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine.
Maryland requires commercial insurers to provide mental health coverage on parity with medical/surgical benefits under Maryland's mental health parity statute and federal MHPAEA. This means UnitedHealthcare cannot impose more restrictive prior authorization, visit limits, or cost-sharing on Spravato than on comparable medical treatments. For Maryland Medical Assistance (state fee-for-service Medicaid) members, coverage follows the Maryland Medicaid Pharmacy Program PDL/PA criteria; for UnitedHealthcare Community Plan of Maryland (HealthChoice managed-care) members, coverage follows UHC Community Plan policy. Both are separate from this commercial policy. Lumin Health verifies your specific plan at consultation.
Two Maryland insurance statutes apply when a commercial carrier reviews a Spravato prior authorization:
Step therapy prohibition for non-FDA-approved alternatives. Under Maryland Insurance Article §15-142, a commercial carrier may not require step therapy when (a) the step-therapy drug is not FDA-approved for the condition being treated, or (b) the prescriber documents that a covered drug ordered for the same condition within the past 180 days was clinically effective. For Spravato — FDA-approved specifically for treatment-resistant depression — this means a carrier cannot require trials of drugs not FDA-approved for TRD as a precondition.
Grievance and adverse-decision review. Under Maryland Insurance Article §15-10A-02, commercial carriers must issue a standard adverse-determination decision within 30 working days, an emergency review within 24 hours, and a behavioral-health emergency-admission review within 2 hours. After internal review, members can request external review through the Maryland Insurance Administration: 120-day filing window, 60-day decision (4 business days for emergencies).
Spravato treatment at Lumin Health in the Maryland/DMV area is available at our Bethesda location, which serves patients from across Maryland, the District of Columbia, and Northern Virginia. Lumin Health Bethesda is REMS-certified per FDA requirements.
How UnitedHealthcare compares with other major Maryland commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes — UHC requires PA for the Spravato medication under its commercial PA/Medical Necessity Policy 2168-10. Lumin Health submits the PA request directly to UnitedHealthcare on your behalf.
Two different antidepressant medications or treatment regimens, each at the maximally tolerated dose for at least 8 weeks. UHC reduced this requirement from three to two in March 2025 per its policy change-control entry. Augmentation regimens (antipsychotics, lithium, or thyroid hormone) count as qualifying trials.
12 months. Reauthorization runs at the same 12-month interval, with current symptom-rating documentation demonstrating remission or clinical response. By comparison, CareFirst BCBS issues a 1-month initial / 3-month continuation, and Aetna runs 6-month reauthorization windows.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with UnitedHealthcare — you don't need to navigate the paperwork or follow-ups. See the appeal section below for the full pathway, including external review through the Maryland Insurance Administration.
For UnitedHealthcare Community Plan of Maryland (UHC's Maryland Medicaid HealthChoice managed-care product) members, Spravato coverage follows UHC Community Plan policy, which is separate from the commercial policy summarized here. For Maryland Medical Assistance (state fee-for-service Medicaid) members, coverage follows the Maryland Medicaid Pharmacy Program PDL/PA criteria. Lumin Health verifies your specific plan at consultation.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date on the Explanation of Benefits (per UHC: "The first request for an appeal should be sent to UnitedHealthcare no later than 180 days after you receive the EOB, unless your plan allows a longer time period."). A small number of UHC commercial plans use a stricter 65-day window — verify on your specific EOB. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Members: file via memberforms.uhc.com or mail per the address printed on your EOB. Phone: Member Services number on your ID card. Providers: file through UHC Provider Portal at uhcprovider.com.
Step 2 — Peer-to-peer (P2P) review. UHC offers peer-to-peer review with strict timing: P2P requests for inpatient cases must be submitted within 3 business days of denial; outpatient cases within 21 calendar days. Your prescriber contacts the UHC clinical reviewer named in the denial letter.
Step 3 — Expedited (urgent) appeal. UHC must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Member or treating provider calls UHC and explicitly requests expedited review with documented medical urgency.
Appeal levels. UHC uses a two-step process: (1) claim reconsideration request, then (2) formal appeal if reconsideration is unsatisfactory. After the second step, members have the right to external review through the Maryland Insurance Administration.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. UHC routes behavioral-health benefits through Optum Behavioral Health. If your Spravato denial originated on the BH benefit, the Optum BH appeal pathway applies. Most commercial Spravato denials are processed under the medical benefit and follow the standard UHC pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the UnitedHealthcare medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days from the date on the Explanation of Benefits (per UHC: "The first request for an appeal should be sent to UnitedHealthcare no later than 180 days after you receive the EOB, unless your plan allows a longer time period."). A small number of UHC commercial plans use a stricter 65-day window — verify on your specific EOB. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Members: file via memberforms.uhc.com or mail per the address printed on your EOB. Phone: Member Services number on your ID card. Providers: file through UHC Provider Portal at uhcprovider.com.
Step 2 — Peer-to-peer (P2P) review. UHC offers peer-to-peer review with strict timing: P2P requests for inpatient cases must be submitted within 3 business days of denial; outpatient cases within 21 calendar days. Your prescriber contacts the UHC clinical reviewer named in the denial letter.
Step 3 — Expedited (urgent) appeal. UHC must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Member or treating provider calls UHC and explicitly requests expedited review with documented medical urgency.
Appeal levels. UHC uses a two-step process: (1) claim reconsideration request, then (2) formal appeal if reconsideration is unsatisfactory. After the second step, members have the right to external review through the Maryland Insurance Administration.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. UHC routes behavioral-health benefits through Optum Behavioral Health. If your Spravato denial originated on the BH benefit, the Optum BH appeal pathway applies. Most commercial Spravato denials are processed under the medical benefit and follow the standard UHC pathway. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the UnitedHealthcare medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
